共 79 条
[11]
Blackmon JT(2018)Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III–IV melanoma: a case series J Immunother Cancer 25 3960-117
[12]
Dhawan R(2018)Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience Ann Surg Oncol 26 4633-492
[13]
Viator TM(2019)Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size Ann Surg Oncol 120 558-87
[14]
Kaufman HL(2019)Correlates of response and outcomes with talimogene laherperpvec J Surg Oncol 36 101-2043
[15]
Amatruda T(2019)Real-world use of talimogene laherparepvec in German patients with stage IIIB to IVM1a melanoma: a retrospective chart review and physician survey Adv Ther 6 MMT19-65
[16]
Reid T(2019)High response rates for T-VEC in early metastatic melanoma (stage IIIB/C–IVM1a) Int J Cancer 67 472-9074
[17]
Andtbacka RHI(2019)Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1) Melanoma Manag 26 82-255
[18]
Kaufman HL(2017)Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual CA Cancer J Clin 20 2035-88
[19]
Collichio F(2015)Evaluating biomarkers in melanoma Front Oncol 545 60-1701
[20]
Harrington KJ(2011)Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma Int J Biol Markers 33 9074-undefined